1. Home
  2. STG vs CRDL Comparison

STG vs CRDL Comparison

Compare STG & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sunlands Technology Group

STG

Sunlands Technology Group

N/A

Current Price

$6.05

Market Cap

112.4M

Sector

Real Estate

ML Signal

N/A

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.01

Market Cap

97.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STG
CRDL
Founded
2003
2017
Country
China
Canada
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
112.4M
97.3M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
STG
CRDL
Price
$6.05
$1.01
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$9.00
AVG Volume (30 Days)
4.2K
383.5K
Earning Date
11-20-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
4.01
N/A
Revenue
$285,589,112.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.48
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.28
$0.77
52 Week High
$15.00
$1.59

Technical Indicators

Market Signals
Indicator
STG
CRDL
Relative Strength Index (RSI) 50.53 49.59
Support Level $5.84 $0.94
Resistance Level $6.12 $1.03
Average True Range (ATR) 0.27 0.04
MACD 0.03 0.00
Stochastic Oscillator 53.52 59.09

Price Performance

Historical Comparison
STG
CRDL

About STG Sunlands Technology Group

Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Share on Social Networks: